Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miglitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 9/20 | 1.00 |
| ▸ | MGAM known ✓ | O43451 | 3/20 | 1.00 |
| ▸ | GBA1 | P04062 | 5/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LCT | P09848 | 1/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 0.88 |
| ▸ | GBA2 | Q9HCG7 | 13/20 | 0.68 |
| ▸ | UGCG | Q16739 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miglitol SCHEMBL15669407 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL9207953 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL5727959 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL20402709 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL6545551 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL23892585 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL15269512 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL682218 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL22593 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 | |
| Miglitol SCHEMBL25887976 | 1.00 | GAA (1.00) | GAAGBA1MGAMSITDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646931-A9 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | Francisco Aragon S.L.U (ES) | 2025-12-24 | — | — | EP | disclosed |
| EP-4646931-A1 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | Francisco Aragon S.L.U (ES) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024089310-A1 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | FRANCISCO ARAGÓN S.L.U (ES) | 2024-05-02 | — | — | WO | disclosed |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-05-19 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-20160331701-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | MCMASTER UNIVERSITY (CA) | 2016-11-17 | — | — | US | disclosed |
| US-20160331701-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | MCMASTER UNIVERSITY (CA) | 2016-11-17 | — | — | US | disclosed |
| US-9415025-B2 | Methods of treating Parkinson's disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2016-08-16 | — | — | US | disclosed |
| US-9415025-B2 | Methods of treating Parkinson's disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2016-08-16 | — | — | US | disclosed |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-04-11 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| WO-2009038695-A1 | METHOD OF TREATING GAUCHER DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075960-A1 | Method of treating gaucher disease | GBA1, GAA, GBA3 | GAA 2/4885MGAM 44/4885GBA1 1/4885 |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | GAA 3/4885MGAM 54/4885GBA1 1/4885 |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | GBA1, GAA, GBA3 | GAA 2/4885MGAM 44/4885GBA1 1/4885 |
| US-20160331701-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | GAA 3/4885MGAM 54/4885GBA1 1/4885 |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | GAA 3/4885MGAM 54/4885GBA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.